Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)-Reference-Cited by-同舟云学术

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

Published:2024-02 Issue:2 Volume:14 Page:453-468
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Reich Kristian^ORCID,Bianchi Luca,Khemis Abdallah,Maul Julia-Tatjana,Tsianakas Athanasios,Schempp Christoph M.,Petersen Kim,Noergaard Mia M.,Puig Lluis

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-023-01092-x.pdf

Reference23 articles.

1. Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Daudén E, Conrad C, Mendes-Bastos P, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–79.

2. Kim BR, Kim M, Yang S, Choi CW, Lee KS, Youn SW. Persistent expression of interleukin-17 and downstream effector cytokines in recalcitrant psoriatic lesions after ustekinumab treatment. J Dermatol. 2021;48(6):876–82.

3. Krueger J, Langley RG, Nigen S, Kasparek T, Comite GD, Ortmann CE, Garcet S, Kolbinger F, Reich K. Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: the ARROW study. Exp Dermatol. 2023. https://doi.org/10.1111/exd.14828.

4. Tomalin LE, Russell CB, Garcet S, Ewald DA, Klekotka P, Nirula A, Norsgaard H, Suàrez-Fariñas M, Krueger JG. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis. J Allergy Clin Immunol. 2020;145(3):922–32.

5. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65-68.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study;Journal of Clinical Medicine;2024-04-26